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Redirecting Human T Lymphocytes Toward Renal Cell
Carcinoma Specificity by Retroviral Transfer 
of T Cell Receptor Genes
BORIS ENGELS,1,2 ELFRIEDE NOESSNER,3 BERNHARD FRANKENBERGER,3
THOMAS BLANKENSTEIN,2,4 DOLORES J. SCHENDEL,3 and WOLFGANG UCKERT1,2
ABSTRACT
Adoptive T cell therapy of renal cell carcinoma (RCC) is limited by the difficulty in generating sufficient num-
bers of RCC-reactive T cells in vitro. To circumvent this problem, we cloned T cell receptor (TCR)  and 
chains from a tumor-infiltrating lymphocyte clone specific for an RCC tumor antigen and transferred the
TCR into human T cell lines and primary T lymphocytes. Efficient TCR expression in primary T lympho-
cytes was obtained only with a mouse myeloproliferative sarcoma virus (MPSV)-based retroviral vector, not
with a Moloney murine leukemia virus (MLV)-based vector, although both viral supernatants were similar
in titer, as shown by analysis of copy number integration in transduced T cells. Reverse transcription-poly-
merase chain reaction analysis revealed a higher amount of TCR-encoding transcripts when T cells were
transduced with the MPSV vector in comparison with the MLV vector, indicating that high TCR expression
levels can be achieved by appropriate cis-regulatory vector elements. The biological activity of the transferred
TCR was shown by specific lysis of RCC cells (51Cr release assay) and by interferon  and tumor necrosis
factor  release (enzyme-linked immunosorbent assay) in an antigen-specific and HLA-A*0201-restricted fash-
ion. Comparison of the redirected T lymphocytes with the original tumor-infiltrating lymphocyte clone re-
vealed similar killing and cytokine secretion capabilities. The functional activity of TCR-redirected T lym-
phocytes was stable over time. The results demonstrate that use of an optimized retroviral vector yielded a
high TCR transduction efficiency and stable and high TCR expression in primary human T lymphocytes and
redirected their specificity toward RCC cells.
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OVERVIEW SUMMARY
The therapeutic efficacy of adoptively transferred cytotoxic T
lymphocytes (CTLs) has been demonstrated in clinical trials.
It is, however, limited by the difficulty in generating sufficient
amounts of CTLs in vitro. Gene therapy approaches include
the genetic engineering of T cell specificity by T cell receptor
(TCR) gene transfer. It was demonstrated that the number of
TCR molecules on the T cell is important for its function. An
efficient transfer system that yields high transduction effi-
ciency and strong and stable transgene expression is a pre-
requisite to achieve effector function for redirected T cells.
We used an improved retroviral vector and transferred a re-
nal cell carcinoma (RCC)-reactive TCR. The redirected pe-
ripheral blood lymphocytes of healthy donors gained speci-
ficity for an RCC tumor antigen. The reprogrammed T cells
showed cytokine secretion and tumor cell killing similar to the
original tumor-infiltrating lymphocyte clone.
INTRODUCTION
RENAL CELL CARCINOMA (RCC) is considered to be one ofthe few immunogenic tumor entities. In some patients, par-
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tial or complete remission was observed after treatment with
various forms of immunotherapy. Studies on allogeneic stem
cell transplantation have shown partial success in treating met-
astatic RCC (Childs et al., 2000; Ueno et al., 2003). Adoptive
T cell transfer has proved effective for the treatment of cy-
tomegalovirus (CMV) disease, Epstein–Barr virus-positive
(EBV) lymphoma, and leukemia (Kolb et al., 1990; Rooney
et al., 1995; Walter et al., 1995). Preliminary studies indicate
that adoptive T cell therapy also has potential for melanoma
treatment (Dudley et al., 2002). Treatment of other cancer en-
tities via adoptive transfer is difficult for several reasons. The
poor immunogenicity of many tumors is one reason, as it leads
to difficulty in isolating tumor-reactive cytotoxic T lympho-
cytes (CTLs) from tumors. This occurs because of low num-
bers of tumor-infiltrating lymphocytes (TILs) or their poor state
of reactivity (tolerogenic T cells). For adoptive transfer, TILs
need to be amplified to large numbers, which is often not feasi-
ble. The genetic redirection of patient peripheral blood lympho-
cytes (PBLs) toward a desired reactivity is a promising approach
to overcome these problems. The successful modification of PBL
specificity through retroviral transfer of T cell receptor (TCR)
or chimeric antibody receptor genes has been shown (reviewed
in Eshhar, 1997; Hombach et al., 2002; Schumacher, 2002).
With regard to human tumor-associated antigens, however, only
TCRs recognizing melanoma or a minor histocompatibility anti-
gen have so far been transferred into human PBLs (MART-1
[Clay et al., 1999], gp100 [Schaft et al., 2003], and mHag HA-
2 [Heemskerk et al., 2003]). Here we describe the generation
of RCC-specific CTLs by TCR  and  chain transfer. The
TCR is derived from a cloned TIL line isolated from an RCC
patient (Schendel et al., 1993). It recognizes a yet unknown
RCC tumor antigen in an HLA-A*0201-restricted manner
(Jantzer and Schendel, 1998). For transfer, the TCR was cloned
into two different retroviral vectors: a Moloney murine leuke-
mia virus (MLV) vector and a vector optimized for gene trans-
fer into T lymphocytes (MP71) (Engels et al., 2003). The
LXSN-based vector is a MLV-derived vector (Miller and Ros-
man, 1989) that has been used as a basis for several more ad-
vanced MLV vectors (MFG [Dranoff et al., 1993]).The opti-
mized vector MP71 contains several cis-regulatory elements
that drive high-level and long-lasting transgene expression in
primary T lymphocytes. Strong transgene expression is manda-
tory in many settings where the amount of expressed protein
directly correlates with function, as, for example, in the case of
TCRs (Labrecque et al., 2001; Heemskerk et al., 2004). In this
study, we show successful expression of a TCR recognizing an
as yet unidentified RCC antigen on retrovirally transduced
PBLs. The redirected T lymphocytes express sufficient amounts
of the TCR to mount effector functions on specific stimulation,
which are similar in magnitude to those seen with the original
TIL clone.
MATERIALS AND METHODS
Cell lines and primary cells
293-10A1 packaging cells (Farson et al., 1999) were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal calf serum (FCS;
Greiner, Frickenhausen, Germany). The human T cell line
HuT78 (TIB161; American Type Culture Collection [ATCC],
Manassas, VA), a CD4 cutaneous T cell lymphoma line, was
cultured in RPMI 1640 medium with 10% FCS, 10 mM HEPES,
and 2 mM glutamine. The proerythroleukemic cell line K-562
(CCL-243; ATCC) and the Burkitt’s lymphoma cell line Daudi
(CCL-213; ATCC) were cultured in RPMI 1640 medium sup-
plemented with 10% FCS, 2 mM glutamine, 1 mM sodium pyru-
vate, and penicillin–streptomycin (100 U/ml) (“standard growth
medium”). The following cell lines were established from RCC
patients and cultured in standard growth medium: NKC-26,
SV40 large T antigen-transformed normal kidney cells of pa-
tient 26; LCL-26, an EBV-transformed B-lymphoblastoid cell
line of patient 26; and RCC-26 and RCC-53, renal cell carci-
noma tumor cells of patients 26 and 53, respectively. TIL-26,
a tumor-infiltrating lymphocyte clone of patient 26 (Schendel
et al., 1993), was cultured in RPMI 1640 medium supplemented
with 2 mM L-glutamine, 1 mM sodium pyruvate, 7.5% heat-in-
activated FCS, 7.5% heat-inactivated pooled human serum, and
recombinant human interleukin 2 (rhIL-2; 50 U/ml) (Roche Ap-
plied Science, Mannheim, Germany). TIL-26 cells were stim-
ulated bimonthly with irradiated (100 Gy, using as 137Cs source
a Gammacell 40, Atomic Energy of Canada, Ottawa, ON,
Canada) IL-2-secreting autologous RCC-26 cells (Pohla et al.,
2000), irradiated (50 Gy) pooled allogeneic peripheral blood
mononuclear cells (PBMCs), and irradiated (150 Gy) EBV-
transformed allogeneic B-LCL. Fresh medium was given bi-
weekly and TILs were split when cells were confluent. For func-
tional assays measuring antigen-specific cytotoxicity or
induction of cytokine secretion TILs were used on days 7 and
14, respectively, after the last stimulation. Human peripheral
blood lymphocytes (PBLs) were isolated from healthy donors
by Ficoll gradient centrifugation (Seromed-Biochrom, Berlin,
Germany) and stimulated for 72 hr with rhIL-2 (50 U/ml) and
immobilized anti-CD3 and anti-CD28 monoclonal antibodies
(mAbs; BD Biosciences Pharmingen, San Diego, CA) as de-
scribed (Uckert et al., 2000). PBLs were cultured in RPMI 1640
medium supplemented with 10% FCS, 2 mM glutamine, 10 mM
HEPES, penicillin–streptomycin (100 U/ml), and rhIL-2 (10
U/ml), if not stated differently. For monthly restimulation 2 
105 PBLs were seeded into a well of a 24-well plate. PBMCs
(3.2  106) from two donors, irradiated with 30 Gy, rhIL-2 (50
U/ml), and anti-CD3 mAb (30 ng/ml), were added to the wells.
All tissue culture media and additives were purchased from
GIBCO (Karlsruhe, Germany).
Construction of retroviral vectors and production of
viral supernatants
TCR  and  chains were derived from a TIL clone isolated
from RCC patient 26 (TIL-26; V20-J22 [TRAV4*01-
TRAJ22*01] and V22-J2.7 [TRBV2*03-TRBJ2-7*01], re-
spectively; Jantzer and Schendel, 1998). Total RNA was iso-
lated with RNA-Bee (Tel-Test, Friendswood, TX). After the
generation of cDNA by random primers and Moloney murine
leukemia virus reverse transcriptase (M-MLV-RT; USB, Cleve-
land, OH), the chains were amplified with oligonucleotides
V20sal sense (5-GTC GTC GAC CAC CAT GAG GCA AGT
G-3), Cxho antisense (5-CAC TCG AGT CAG CTG GAC
CAC AGC-3), V22not sense (5-CGT GCG GCC GCC ACC
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ATG GAT ACC TGG C-3), and Cxba antisense (5-GCA
TCT AGA CTA GCC TCT GGA ATC CTT TCT CTT G-3).
They were subsequently cloned into the plasmid pPBS, con-
taining the poliovirus internal ribosomal entry site (IRES,
kindly provided by W.F. Anderson) (Morgan et al., 1992), to
obtain pPBSIRES. The IRES fragment including the
Kozak sequence was then cloned into two retroviral vectors.
The vector plasmid pLIRES (pL-tcr, 7235 bp) is a deriva-
tive of pLXSN (Miller and Rosman, 1989). For the construc-
tion of pL-tcr the simian virus 40 promoter (S) and the neomycin
resistance gene (N) were excised from pLXSN by HpaI and
NaeI digestion (all restriction enzymes were purchased from
Amersham Biosciences/GE Healthcare, Freiburg, Germany)
and replaced by the IRES fragment, obtained by XhoI re-
striction of pPBSIRES, followed by incubation with Klenow
fragment (USB) and a final NotI digestion. The vector plas-
mid pMP71IRESPRE (pMP-tcr, 7893 bp) is based on
pMP71GPRE (Engels et al., 2003). For the development of
pMP-tcr, pMP71GPRE was partially digested with EcoRI, in
order to maintain the posttranscriptional regulatory element
(PRE). After incubation with Klenow fragment the vector was
digested with NotI and the IRES fragment, excised as de-
scribed above, was inserted into the vector. The green fluores-
cent protein (GFP)-encoding vector pMP71GPRE was used as
a mock control throughout this study, and is named pMP-gfp.
Stable producer cell clones were generated by cotransfection
of 293-10A1 packaging cells with either of the retroviral vec-
tor plasmids and the plasmid pWLneo (Stratagene, Heidelberg,
Germany), using calcium phosphate precipitation (Amersham
Pharmacia Biotech) (Uckert et al., 2000). High-titer virus vec-
tor particle-containing supernatant (viral supernatant) was pro-
duced in 175-cm2 tissue culture flasks (Corning Costar, Bo-
denheim, Germany) at 37°C and stored in aliquots at 80°C.
Transduction of T cells
HuT78 cells and stimulated PBLs were transduced in 24-
well non-tissue culture plates coated with RetroNectin (TaKaRa
Bio, Otsu, Japan) as described (Uckert et al., 2000). HuT78
cells (1  105 per well, and per ml) or PBLs (2  105 per well,
and per ml) were transduced for 24 hr with 1 ml of viral su-
pernatant supplemented with protamine sulfate (4 g/ml;
Sigma-Aldrich Chemie, Munich, Germany). For PBLs, rhIL-2
(50 U/ml) was added. Cells were then transferred to culture
flasks and cultured as described above.
Flow cytometric analysis and magnetic cell sorting
Cells were stained with fluorescein isothiocyanate (FITC)-
or phycoerythrin (PE)-conjugated anti-TCR chain V22 mAb
(Serotec, Oxford, UK) or with anti-CD3, anti-CD4, or anti-CD8
mAb (BD Biosciences Pharmingen). Data acquisition and anal-
ysis was performed on a FACSCalibur (BD Biosciences Im-
munocytometry Systems, San Jose, CA) using CellQuest Pro
software.
To enrich for V22-positive cells, MP-tcr-transduced PBLs
were stained with PE-conjugated anti-V22 mAb and subse-
quently with anti-PE microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany). The stained cells were thereafter purified
with an autoMACS separator (Miltenyi Biotec) according to the
manufacturer’s instructions.
Genomic DNA polymerase chain reaction
Genomic DNA (gDNA) was isolated from L-tcr-, MP-tcr-,
and nontransduced PBLs on days 11 and 32 posttransduction, us-
ing a DNeasy tissue kit (Qiagen, Hilden, Germany), and subse-
quently treated with DNase-free RNase (Roche Applied Science).
One hundred nanograms and 10 ng of gDNA were employed for
each sample. Forward primer fvb-c (5-GCA GAA CCC CCG
CAA CCA CT-3) and reverse primer rIRES (5-CGA CAT CAC
CGG GGA AAC AGA AG-3) were used to amplify a vector-
specific 450-bp product. As loading control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)-specific primers were used
to generate a 451-bp product (forward primer, 5-ACC ACA
GTC CAT GCC ATC AC-3; reverse primer, 5-TCC ACC ACC
CTG TTG CTG TA-3). PCRs were run in a T personal ther-
mocycler (Biometra, Göttingen, Germany) using Taq DNA
polymerase (Invitrogen, Karlsruhe, Germany). PCR conditions
were 2 min at 94°C; 25, 30, or 35 cycles of 94°C for 30 sec;
68°C for 30 sec and 72°C for 1 min; and a final 10-min incuba-
tion at 72°C for the virus-specific reaction, and with an anneal-
ing temperature of 55°C for GAPDH. PCR products were ana-
lyzed by 1% agarose gel electrophoresis, ethidium bromide
staining, and quantification with the Lumi-Imager F1 and Lumi-
Analyst software (both from Roche Applied Science).
Reverse transcription-polymerase chain reaction
Total RNA was isolated from PBLs on days 11 and 32 post-
transduction with either L-tcr or MP-tcr according to Chom-
czynski and Sacchi (1987). RNA concentration was determined
spectrophotometrically after RNase-free DNase I digestion
(Roche Applied Science). cDNA was synthesized using 1 g
of total RNA, random primers, and reverse transcriptase (RT;
both from Invitrogen) in a 20-l reaction mix. A 0.5- or 0.1-
l volume of cDNA was used per PCR. As negative controls
no-template and no-RT samples were included. Reactions were
run in a Tpersonal thermocycler using Taq DNA polymerase.
The same primers and PCR conditions as for gDNA PCR were
used. PCR products were analyzed by 1% agarose gel elec-
trophoresis, ethidium bromide staining, and quantification with
the Lumi-Imager F1 and LumiAnalyst software.
Cytokine release assay
Target cells (1.5  104) were cocultured with 1.0  104
PBLs or 3.0  103 TIL-26 cells in 96-well round-bottom plates
for 24 hr. The supernatant was removed and tested for inter-
feron  (IFN-) and tumor necrosis factor  (TNF-) content
by enzyme-linked immunosorbent assay (ELISA) (sensitivity,
4 pg/ml; eBioscience, San Diego, CA) according to the manu-
facturer’s protocol. Inhibition assays were performed by adding
MA2.1 (anti-HLA-A2 mAb, 4 g/well; ATCC HB-54), W6/32
(anti-MHC class I Ab, 2 g/well; ATCC HB-95), or MOPC21
(mouse IgG1 isotype control, 4 g/well; Sigma) during cocul-
tivation. K-562 and Daudi cells, which lack MHC class I mol-
ecules, were used as negative controls for stimulation, and anti-
CD3 mAb (BD Biosciences Pharmingen)-coated wells (5
g/ml) were used as a positive control. The data are given as
mean values with standard deviations of duplicates, derived
from one representative experiment. At least two independent
experiments were performed.
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Cytotoxicity assay
Cell-mediated lysis of target cells by T cell clone TIL-26 
and TCR gene-modified PBLs was quantified in a 4-hr 51Cr re-
lease assay. Effector-to-target cell ratios ranged from 20:1 
to 1.25:1, employing 2.0  103 target cells. Spontaneous re-
lease was determined by incubating target cells alone, and the
maximal release was determined by directly counting labeled
cells. The percentage of cytotoxicity was calculated as: percent
specific lysis  [(cpmexperimental  cpmspontaneous)/(cpmmaximal 
cpmspontaneous)]  100. Duplicate measurements of four-step
titration of effector cells were used for all experiments. K-562
and Daudi cells were used as controls. Results shown represent
mean values and standard deviations from one of two inde-
pendent experiments.
RESULTS
Expression of RCC-specific TCR in T cell lines and
primary human T lymphocytes is superior with 
MPSV-based vector
Rearranged TCR  and  chains from TIL-26 were cloned
into MLV (pLXSN)- and MPSV (pMP71)-based vectors and
named L-tcr and MP-tcr, respectively (Fig. 1A). Viral super-
natants containing either vector were used to transduce HuT78
T cells and primary T lymphocytes of three different donors.
Surface expression of the exogenous TCR was analyzed by flow
cytometry using an anti-TCR chain V22 mAb. Both the L-tcr
and MP-tcr vectors led to transgene expression in HuT78 cells
(Fig. 1B). However, a difference could be seen in the percent-
age of V22-expressing T cells and also in the level of TCR
surface expression, measured as mean fluorescence intensity
(MFI). Forty-six percent of L-tcr-transduced T cells expressed
V22 with an MFI of 44, whereas 83% of MP-tcr-transduced
T cells expressed V22 with an MFI of 74. Such an expression
pattern was observed in several experiments (data not shown).
The difference in transgene expression by the two vectors was
even more pronounced in transduced primary T lymphocytes,
where only MP-tcr led to strong TCR expression. In the ex-
periment shown in Fig. 1B, transduction of PBLs of donor 1
with MP-tcr yielded 52% V22-positive cells, compared with
7% obtained with L-tcr. This finding was confirmed in several
experiments performed at different times with three different
donors (Table 1). Looking at the expression of V22 in L-tcr-
transduced PBLs in more detail, an increase of only low V22-
expressing cells can be observed. The 7% of V22-positive
PBLs include the 3.5% endogenously V22-expressing cells, as
seen for the nontransduced PBLs (thin lines in Fig. 1B). In MP-
tcr-transduced primary T lymphocytes many cells expressed the
transgenic TCR at lower levels compared with the endogenous
TCR; however, a substantial number of cells expressed the TCR
at similar levels. Compared with L-tcr-transduced PBLs, MP-
tcr-transduced cells showed significantly higher expression lev-
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FIG. 1. The retrovirally encoded TCR-26 
chain is strongly expressed on the cell surface
of MP-tcr-transduced T cells. (A) Schematic
representation of vector constructs used in this
study. The size of the retroviruses is shown. Ar-
rows indicate the position of primers used for
titration by gDNA PCR and RT-PCR analysis
in Fig. 2. IRES, poliovirus internal ribosomal
entry site; LTR, long terminal repeat; MLV,
Moloney murine leukemia virus; MPSV,
myeloproliferative sarcoma virus; MESV
leader, modified murine embryonic stem cell
virus leader sequence; PRE, woodchuck he-
patitis virus posttranscriptional regulatory ele-
ment; TCR, T cell receptor. (B) T cell line
HuT78 and PBLs were transduced with either
vector and analyzed 4 or 20 days posttrans-
duction, respectively. TCR  chain surface ex-
pression is visualized by staining nontrans-
duced cells (thin line) and transduced cells
(thick line) with a PE-conjugated anti-V22
mAb. The numbers indicate the percentage of
V22-positive cells within the whole cell pop-
ulation (cells were gated on live cells, of which
99% were CD3 positive) and the mean fluo-
rescence intensity (MFI) of the cell population
within the marked region. The MFI was calcu-
lated for the difference between transduced and
nontransduced cells, in order to exclude en-
dogenous V22-positive cells. One representa-
tive result from donor 1 is shown.
els (MFI, 27 versus 14). We cannot exclude the potential forma-
tion of mixed hybrid TCRs of TCR-26 chains with endogenous
TCR chains for both transduced Hut78 cells and PBLs. This would
lead to a lower amount of TCR-26-positive compared with V22-
positive cells. A vector control (MP-gfp) did not increase V22
expression (data not shown).
Both vectors transduce PBLs at similar rates
PBLs were transduced with viral supernatants harvested from
producer cell clones selected for high viral titer production. As
neither of the vectors contains a selectable marker and there-
fore titration by transduction of indicator cells was not possi-
ble, the relative titer was determined through analysis of copy
number integrations. Hence gDNA was prepared from L-tcr-,
MP-tcr-, and nontransduced PBLs of two donors on days 11
and 32 posttransduction. PCRs specific for the viral genomes
were performed, and the bands were subsequently quantified.
The amount of gDNA employed per reaction (100 and 10 ng)
was confirmed by GAPDH-specific amplification. Furthermore,
PCR samples were analyzed after 25, 30, and 35 cycles of am-
plification, altogether giving comparable results. In Fig. 2A
donor 1 samples amplified for 30 cycles are shown. Bands were
quantified and Boehringer light units (BLU) were plotted (Fig.
2B). Similar band intensities were obtained for cells transduced
with either vector, demonstrating similar numbers of integrated
viral genomes. No signals were obtained when nontransduced
PBLs and template-negative controls were analyzed. This
clearly shows that the T cells were transduced at similar rates,
indicating comparable viral titers of L-tcr and MP-tcr.
To further analyze the discrepancy between similar viral
copy integration and differing TCR expression in L-tcr- and
MP-tcr-transduced PBLs, we performed RT-PCR analysis. To-
tal RNA was isolated from L-tcr-, MP-tcr-, and nontransduced
PBLs of two donors on days 11 and 32 posttransduction. For
RT-PCR we employed two different cDNA amounts, using the
same virus- and GAPDH-specific primers described above. Un-
like the gDNA PCR, the RT-PCR showed a clear difference in
the amount of TCR transcripts between L-tcr- and MP-tcr-trans-
duced PBLs. One experiment representative of two for donor
1 is shown in Fig. 2C and the respective bar diagram is shown
in Fig. 2D. For days 11 and 32 posttransduction more TCR-en-
coding transcript could be detected in MP-tcr-transduced PBLs
compared with L-tcr-transduced T cells. On the basis of
GAPDH-corrected virus band intensities, a 4-fold higher
amount of TCR transcripts was found for MP-tcr-transduced
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TABLE 1. TRANSDUCTION RATES FOR PBLs OF DIFFERENT
DONORS IN INDEPENDENT EXPERIMENTS
PBL donor a
MP-tcr/L-tcr (% V22)
Experiment 1b 2 3
1 32/3d —c 19/50
2 37/3d 28/3 —
3 20/6d 16/6 —
4 52/7d —c 35/—
a2.5–3.5% V22 cells represent endogenous V22 expres-
sion.
bFunctional data and molecular analysis are shown for donor 1.
c
—, not determined, as transduction was not performed.
dData shown in Fig. 1B.
FIG. 2. MP-tcr-transduced PBLs contain similar numbers of in-
tegrated viral genomes as L-tcr-transduced PBLs, but more TCR-
26 transcripts. Nontransduced, L-tcr-transduced, and MP-tcr-
transduced PBLs (donor 1) from days 11 and 32 posttransduction
were analyzed for integrated viral genomes and TCR transcripts.
(A) gDNA PCR: 100 and 10 ng of gDNA were amplified with
primers specific for both vectors (450 bp; see Fig. 1A) and for
GAPDH (451 bp). Shown are samples analyzed after 30 cycles
of amplification, which were run in a 1% agarose gel and stained
with ethidium bromide. (B) Ethidium bromide-stained DNA
bands were digitally quantified. BLU, Boehringer light units. (C)
RT-PCR with the same primers as used in (A); 0.5 and 0.1 l of
cDNA (derived from a 20-l RT reaction with 1 g of total RNA)
were amplified for 30 cycles and visualized as in (A). (D) Digi-
tal quantification as in (B). *4.37  106 BLU.
PBLs at both time points. Nontransduced cells led to no virus-
specific signal. No signals were amplified when either template
or reverse transcriptase were omitted from the PCR (data not
shown). These results confirm the data obtained for TCR pro-
tein expression analysis by flow cytometry and indicate that the
strong cis-regulatory elements in the MPSV-based retroviral
vector are responsible for the higher TCR expression.
Redirected PBLs are stimulated by RCC-26 cells
To assess the function of virally expressed TCR, we performed
stimulation assays. L-tcr-, MP-tcr-, and nontransduced PBLs of
three different donors were cocultured with the tumor cell line
RCC-26, which expresses the peptide–MHC ligand for the trans-
genic TCR. Secretion of IFN- reflected stimulation of the T
cells by RCC-26 cells. Shown are representative results obtained
for PBLs of donor 1 (Fig. 3). MP-tcr-transduced PBLs were
clearly activated by RCC-26 cells (IFN-, 1421 pg/ml). In con-
trast, L-tcr-transduced PBLs secreted less IFN-, in fact only
slightly more than did nontransduced PBLs (304 versus 244
pg/ml). The general ability of all cells to be activated and to se-
crete cytokines was proven by unspecific, redirected stimulation
(anti-CD3 mAb, data not shown). The marginal increase in IFN-
 secretion by L-tcr-transduced PBLs, compared with nontrans-
duced cells, may indicate that the TCR expression by L-tcr is not
sufficient to trigger TCR-mediated T cell stimulation. The MP-
tcr-encoded tumor-specific TCR was, however, expressed at lev-
els sufficient to induce activation of the transduced T cells on
cocultivation with the RCC-26 cell line. Referring to the flow
cytometric analysis, the higher percentage of V22-positive cells
allowed activation of the MP-tcr-transduced PBL population. As
hardly any TCR-related activity was detected for L-tcr-trans-
duced PBLs, all further experiments were conducted with MP-
tcr-transduced T cells only.
Redirected PBLs are stimulated by target cells as
efficiently as the original TIL clone
The comparison of MP-tcr-transduced PBLs with the origi-
nal TIL-26 cells, both carrying the same TCR, revealed simi-
lar responses to RCC-26 cells. In this assay, the number of ef-
fector cells was adjusted on the basis of the percentage of V22-
positive cells. According to flow cytometry analysis on the day
of assay, one-third of the transduced PBLs were V22 positive,
compared with 100% of the TIL-26 cells (data not shown).
Therefore, we employed 1  104 MP-tcr-transduced PBLs or
3  103 TIL-26 cells per well. The production of IFN- and
TNF- on stimulation of the cells of three different donors
showed that TCR-26 gene-modified PBLs developed a similar
cytokine response as TIL-26 cells, which express the same TCR
endogenously (Fig. 4). The MP-tcr-transduced PBLs of donor
1 secreted, per milliliter, 1790 pg of IFN- and 230 pg of TNF-
, whereas TIL-26 cells secreted 1850 pg of IFN- and 260 pg
of TNF- (Fig. 4A and B). The similar amount of both cyto-
kines secreted by each V22-positive T cell population argues
for physiological TCR transgene expression in the transduced
PBLs. MP-gfp- and nontransduced PBLs did not respond to
RCC-26 cell stimulation. All cells, however, responded simi-
larly to redirected stimulation with anti-CD3 mAb (data not
shown).
Using a set of different target cells, the specificity of redi-
rected PBLs was investigated. MP-tcr-transduced PBLs were
not stimulated by the allogeneic renal cell carcinoma cell line
RCC-53, the autologous normal kidney cell line NKC-26, or
the autologous lymphoblast cell line LCL-26, which are all neg-
ative for the peptide-MHC ligand for the transgenic TCR, or
by Daudi cells, which are MHC class I negative (Fig. 4C and
D, solid columns). This indicated antigen-specific recognition
by the transgenic T cells. Furthermore, the redirected PBLs
showed the same specificity as seen for the TIL-26 clone (Fig.
4C and D, open columns).
Antigen-specific recognition by redirected PBLs is
HLA-A2 restricted
To further confirm specific TCR peptide–MHC interaction
resulting in cytokine secretion, we performed blocking assays
with various antibodies (Fig. 5). Using the HLA-A2-specific
mAb MA2.1 as a blocking reagent, 81% less IFN- was pro-
duced by RCC-26 cell-stimulated MP-tcr-transduced PBLs of
donor 1. When the anti-MHC class I antibody W6/32 was used,
95% less IFN- was secreted. The isotype control mAb
(MOPC21) did not reduce the amount of IFN- secretion. A
similar pattern of blocking was also observed for coculture of
RCC-26 cells with additional TCR-transduced PBLs of two
donors and the TIL-26 clone that expresses the TCR naturally
(data not shown). These data demonstrate that the stimulation
of transduced PBLs was based on TCR-mediated recognition
of an HLA-A2-restricted RCC tumor antigen, as has been
shown for the original TIL-26 cells (Schendel et al., 1997;
Jantzer and Schendel, 1998).
Redirected PBLs and TIL-26 cells show similar lytic
activity against RCC-26 cells
Next we evaluated the cytotoxicity of redirected PBLs of
the three different donors. For a comparison of tumor cell 
lysis by MP-tcr-transduced PBLs and TIL-26 cells on a cell-
to-cell basis, we enriched MP-tcr-transduced PBLs for V22-
positive T cells by MACS, which yielded an 86% V22-
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FIG. 3. MP-tcr-transduced but not L-tcr-transduced PBLs se-
crete IFN- on stimulation with RCC-26 cells. Cytokine was
measured in the supernatant of stimulated PBLs. Values shown
represent mean values and standard deviations of duplicates ob-
tained by ELISA. The experiment was performed three times
and PBLs of three donors were analyzed. Effector cells (1.0 
104; MP-tcr-transduced PBLs [solid columns], L-tcr-transduced
PBLs [dotted columns], or nontransduced PBLs [hatched
columns]) were cultivated alone (none) or with 1.5  104 RCC-
26 cells. Assays were performed 12 days after transduction.
positive cell population for donor 1 (Fig. 6A). Enriched MP-
tcr-transduced PBLs and the original TIL-26 clone lysed
RCC-26 cells to similar extent (Fig. 6B). Thus, as has been
observed for the cytokine response, MP-tcr-transduced PBLs
had antitumor activity comparable to that of TIL-26 cells.
Mock-transduced and nontransduced PBLs showed similar
low background lysis.
The specificity of the lysis reaction was shown by incu-
bating the same effector cells with different target cells (Fig.
6C). Again, no reactivity toward autologous control cells, that
is, NKC-26 and LCL-26 cells, was measured, nor were RCC-
53 cells lysed. The MHC class I-negative K-562 line, which
is a control for natural killer cell activity, was also not lysed.
Mock-transduced and nontransduced PBLs exhibited some
degree of lytic activity against RCC-26 cells. Because a sim-
ilar level of activity was observed against MHC class I-neg-
ative Daudi cells (data not shown) it is most likely that this
activity is nonspecific, induced by exposing PBLs to IL-2 and
anti-CD3/anti-CD28 mAbs before retroviral transduction.
The pattern of lytic activity, in particular the clear distinc-
tion of RCC-26 cells from normal kidney cells, demonstrated
that the transduced PBLs specifically lysed cells that present
the tumor epitope specific for the transgenic TCR.
MP-tcr-driven TCR expression is stable over time
After expression and function of the transferred TCR-26 cells
were shown for MP-tcr-transduced PBLs, the duration of trans-
gene expression was analyzed. In two independent experiments,
each with two donors, PBLs transduced with the MP-tcr or the
L-tcr vector were cultured in vitro for up to 111 days and V22
expression was monitored over time. To maintain the cultures,
transduced cells were unspecifically restimulated with irradi-
ated feeder cells and anti-CD3 mAb every 30 days. MP-tcr-, L-
tcr-, and nontransduced PBLs proliferated similarly at each
round of stimulation (data not shown). Flow cytometry data ob-
tained for transduced PBLs of donor 1 on days 5 and 111 post-
transduction show 18 and 15% for MP-tcr, respectively, and 6
and 3% for L-tcr, respectively, of V22-positive cells (Fig. 7A).
In Fig. 7B V22 expression is plotted against time. After 111
days, 83% of the initial V22-positive MP-tcr transduced PBLs
still expressed TCR-26, whereas only 26% of L-tcr transduced
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FIG. 4. MP-tcr-transduced PBLs and TIL-26 secrete similar amounts of IFN- and TNF- on stimulation with RCC-26 cells.
Cytokines were measured in the supernatant after cocultivation of 1.0  104 (PBL) or 3.0  103 (TIL-26) effector cells and 1.5 
104 target cells for 24 hr. Values shown represent mean values and standard deviations of duplicates obtained by ELISA. Ex-
periments were performed twice and PBLs of three donors were analyzed, altogether giving similar results. (A) IFN- ELISA
and (B) TNF- ELISA, utilizing TIL-26 cells (open columns) and MP-tcr-transduced (solid columns), MP-gfp-transduced (striped
columns), and nontransduced PBLs (shaded columns) cocultivated with RCC-26 cells. Assays were performed on day 16 post-
transduction. (C) IFN- ELISA and (D) TNF- ELISA, utilizing TIL-26 cells (open columns) and MP-tcr-transduced PBLs (solid
columns), which were cocultivated with RCC-26 [same result as shown in (A) and (B)], RCC-53, NKC-26, LCL-26, and Daudi
cells as indicated.
cells retained TCR-26 expression. These data clearly indicate
that transgene expression by MP-tcr is stable over time, whereas
it decreases when using L-tcr.
Further analysis of the long-term in vitro-cultured cells
showed that TCRs were still functionally active on day 55 post-
transduction as indicated by IFN- release (data not shown),
similar to those of cells used 14 days posttransduction (Fig. 3).
Taken together, the MP-tcr vector guarantees high transgene
expression over more than 100 days, whereas the L-tcr vector
fails to express the TCR at high and constant levels.
DISCUSSION
In this study we show the transfer of antitumor specificity
from a TIL clone established from an RCC patient to PBLs of
healthy donors. Redirected T lymphocytes stably expressed the
TCR on the cell surface, were specifically activated by RCC-
26 tumor cells as shown by cytokine secretion on coculture, and
gained similar killing capabilities as the originally isolated TIL
clone. To transfer the TCR genes, we employed two different
retroviral vectors: a Moloney murine leukemia virus (MLV)-
derived vector (LXSN) (Miller and Rosman, 1989) and an
MPSV-derived vector (MP71) (Schambach et al., 2000). With
both, we generated MLV-10A1-pseudotyped vector particles to
efficiently transduce PBLs (Uckert et al., 2000). The optimized
MPSV-based vector (MP-tcr) yielded strong and durable TCR
expression associated with the ability to perform effector func-
tion, whereas the MLV vector (L-tcr) failed to express suffi-
cient amounts of TCR to exert effector function.
These results confirm and extend previous data describing
approximately 20-fold higher expression levels of a cytoplas-
mic protein (GFP) in primary human T lymphocytes transduced
with MP71 (MP-gfp) in comparison with LXSN (Engels et al.,
2003). The stronger expression obtained with MP-gfp was not
due to multiple integration events, but could clearly be ascribed
to the stronger cis-regulatory elements of the MP-gfp vector,
as demonstrated by Southern blot and RT-PCR analysis. Now
we demonstrate that the MPSV vector also performs better than
the MLV vector when used to express a complex multimeric
protein such as a TCR, which consists of  and  chain pro-
teins and requires additional proteins of the CD3 complex for
transport to the cell surface. To exclude that the higher TCR
expression level obtained with MP-tcr compared with L-tcr was
due to higher viral titers and consequently multiple integrations,
we employed the most objective criteria for titer estimation and
analyzed the number of integrated viral copies in the transduced
T cells. Both MP-tcr- and L-tcr-transduced T lymphocyte pop-
ulations revealed similar amounts of integrated vector genomes,
as shown by semiquantitative DNA PCR and real-time PCR
(data not shown). Although similar viral titers were used, hardly
any surface expression and no effector function of the trans-
ferred TCR were detected in L-tcr-transduced T lymphocytes.
In contrast, the MP-tcr-transduced PBL bulk culture strongly
expressed TCR-26 and responded to RCC-26 tumor cell stim-
ulation with cytokine secretion and cytotoxicity.
The discrepancy between similar transduction efficiency and
integration rates on the one hand and different transgene ex-
pression on the other is most likely ascribed to the different cis-
regulatory elements of the two retroviral vectors. The strongest
activating effect in the MP71 vector can be attributed to the
modified 5-untranslated region, originating from the murine
embryonic stem cell virus (MESV) (Grez et al., 1990). This
leader sequence contains an artificial splice acceptor site com-
plementing the retroviral splice donor site. In addition, all start
codons have been removed from within the leader sequence.
Consequently, the ATG of the transgene is the first start codon
3 of the promoter (Hildinger et al., 1999). Moreover, the MPSV
long terminal repeat (LTR) promoter and enhancer elements by
themselves improve transgene expression in T lymphocytes
(Schambach et al., 2000; Engels et al., 2003) and lymphohe-
matopoietic cells (Baum et al., 1995; Hildinger et al., 1998).
The MP71-based vectors differ from the related MSCV vectors
(Hawley et al., 1994) in the U3 region of the 3 LTR. The MP71
vector carries the MPSV U3 region (Schambach et al., 2000).
In contrast, MSCV vectors contain the respective PCC4-em-
bryonal carcinoma cell-passaged myeloproliferative sarcoma
virus (PCMV) region (Hilberg et al., 1987; Hawley et al., 1994).
Furthermore, MSCV vectors contain a hybrid leader sequence
of MESV and LNCX origin, whereas the leader of MP71 vec-
tors is solely of MESV origin. Finally, the introduction of the
woodchuck hepatitis virus posttranscriptional regulatory ele-
ment (PRE) into the MP71 vectors accounts for a further in-
crease in the level of transgene expression (Zufferey et al.,
1999). The LXSN vector we have used in this comparison is a
basic, entirely MLV-based vector. Several advanced vectors
based on LXSN have been described, including grafting of T
lymphocytes with antigen receptors (MFG-based pMX [Fujio
et al., 2000; Kessels et al., 2000] and pBullet [Willemsen et al.,
2000]). They were not included in our study. However, data on
GFP expression by MP71 and pBullet revealed higher trans-
gene expression rates in MP71-transduced cells (our unpub-
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FIG. 5. Antigen recognition via the transgenic TCR is HLA-
A2 restricted. MP-tcr-transduced PBLs (1.0  104) and 1.5 
104 RCC-26 cells were cocultivated for 24 hr. Various anti-
bodies were added to the coculture to block TCR peptide–MHC
interactions: MA2.1 (anti-HLA-A2), W6/32 (anti-MHC class
I), and MOPC21 (isotype control). w/o, no target cells. Values
shown are mean values and standard deviations of duplicates
obtained by ELISA. Experiments were performed twice and
PBLs of three donors were analyzed, altogether giving similar
results. Assay was performed on day 18 posttransduction.
lished results). Taken together, the stronger cis-regulatory ele-
ments of MP-tcr in comparison with those of L-tcr lead to su-
perior TCR expression, as shown at the transcriptional level by
RT-PCR analysis and at the translational level by flow cyto-
metric analysis of TCR-26 cell surface expression. The strong
transgene expression by MP-tcr is of particular relevance be-
cause (1) the amount of TCR on the cell surface critically de-
termines the functionality of the gene-modified T cell
(Labrecque et al., 2001) and (2) a high level of TCR expres-
sion is achieved at a low multiplicity of infection (MOI),
thereby potentially reducing the risk of insertional mutagenesis
(Hacein-Bey-Abina et al., 2003; Fehse et al., 2004).
The MP-tcr vector is superior to the L-tcr vector not only re-
garding the level of TCR-26 expression, but also regarding the
duration of TCR-26 expression. This is an indispensable prereq-
uisite for the generation of a sufficient number of TCR-redirected
T lymphocytes for adoptive transfer into patients. In contrast to
the stable TCR-26 expression by MP-tcr transduction, L-tcr-trans-
duced PBLs gradually lost expression over time. Genomic DNA
PCR analysis of transduced PBLs showed that the number of in-
tegrated viral genomes remained similar for both vectors over
time, indicating that the decrease in TCR-26 expression in L-tcr
transduced cells is due to lower expression rates, probably induced
by gene silencing through methylation of the MLV LTR (Jahner
et al., 1982; Challita and Kohn, 1994; Wang et al., 1998).
So far, the majority of genetically engineered tumor-reactive
T lymphocytes have been endowed with TCRs recognizing mel-
anoma-associated antigens (Clay et al., 1999; Schaft et al.,
2003). Furthermore, effector functions of TCR-redirected hu-
man PBL bulk cultures have so far been described only for mel-
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FIG. 6. MP-tcr-transduced PBLs lyse RCC-
26 cells as efficiently as do TIL-26 cells. (A)
Flow cytometric analysis of cells employed for
the lysis assay. MP-tcr-transduced PBLs, V22-
immunoselected transduced PBLs (enr., en-
riched), and TIL-26 cells were stained for CD8
and V22 one day after the lysis assay (cells
were gated on live cells, of which 99% were
CD3 positive). Numbers at bottom right of each
panel indicate the percentage of cells in the
quadrants; numbers in parentheses indicate the
MFI for V22. (B and C) Specific lysis was
evaluated in a 4-hr 51Cr release assay, employ-
ing 2  103 target cells and titered concentra-
tions of effector cells, as indicated by the ef-
fector-to-target ratio (E/T ratio). Data shown
represent mean values and standard deviations
of duplicates from one experiment. Two inde-
pendent experiments were performed and PBLs
of three donors were analyzed on day 12 post-
transduction. (B) Effectors, TIL-26 cells (dotted
line, diamonds), MP-tcr-transduced PBLs (solid
line, solid squares), MP-gfp-transduced PBLs
(solid line, solid circles), and nontransduced
PBLs (solid line, open squares). MP-tcr-trans-
duced PBLs were enriched (enr.) for V22-pos-
itive cells by MACS and used against RCC-26
target cells. (C) Effectors, MP-tcr-transduced,
MP-gfp-transduced, and nontransduced PBLs,
as indicated, were used against targets RCC-26
cells [solid line, solid squares; same results as
shown in (B)], NKC-26 cells (dotted line, solid
diamonds), LCL-26 cells (solid line, open tri-
angles), RCC-53 cells (solid line, open squares),
and K-562 cells (dotted line, solid squares).
anoma-associated gp100 specificity (Morgan et al., 2003). Here
we demonstrate for the first time that RCC tumor cell-specific
CTLs can be generated by the transfer of antigen-specific TCR
into PBLs of healthy donors. We proved the functionality of
the TCR-26-redirected PBLs, using unsorted bulk cultures of
MP-tcr-transduced T lymphocytes. After TCR gene transfer the
PBLs of healthy donors gained HLA-A2-restricted, RCC-spe-
cific effector functions comparable in magnitude to those of the
original TIL clone. In contrast, using the L-tcr vector the ex-
pression levels were not sufficiently high to induce T effector
function by RCC-26 cell stimulation. Notably, in many previ-
ous studies with MLV-derived vectors, only enriched or cloned
TCR-transduced T cells were investigated, indicating a low
TCR expression level by MLV vectors also in other systems
(Clay et al., 1999; Cooper et al., 2000; Heemskerk et al., 2003).
Similar results have been also described in a study using a chi-
meric antibody receptor (Weijtens et al., 2000).
In conclusion, we have demonstrated that PBLs of healthy
donors can be redirected toward tumor antigens by specific TCR
gene transfer. Using an optimized retroviral vector, we gener-
ated PBLs that are specific for an RCC tumor antigen and ex-
ert effector functions of similar strength and specificity as ob-
served for the CTL clone that expresses the TCR endogenously.
The antigen recognized by the transduced TCR-26 is unknown.
Antigen identification requires significant numbers of T cells,
which are often not achieved in RCC investigations. The de-
scribed approach provides an important tool with which to iden-
tify this tumor antigen, as well as those of other TIL clones,
where long-term T cell clones cannot be established. It can be
envisioned that small repertoires of T cells bearing transgenic
TCR to redirect their specificity toward tumors or viruses will
be used in adoptive T cell therapy.
ACKNOWLEDGMENTS
We thank Anna Brandl, Martina Grabbert, and Irmgard Kütt-
ner for excellent technical help and Thomas Kammertöns for
ENGELS ET AL.808
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